These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 34315572)
21. Comparison of the vessel healing process after everolimus-eluting stent and bare metal stent implantations in patients with ST-elevation myocardial infarction. Yano H; Horinaka S; Watahik M; Watanabe T; Ishimitsu T Heart Vessels; 2019 Apr; 34(4):572-582. PubMed ID: 30392104 [TBL] [Abstract][Full Text] [Related]
22. Change in lumen eccentricity and asymmetry after treatment with Absorb bioresorbable vascular scaffolds in the ABSORB cohort B trial: a five-year serial optical coherence tomography imaging study. Suwannasom P; Sotomi Y; Asano T; Koon JN; Tateishi H; Zeng Y; Tenekecioglu E; Wykrzykowska JJ; Foin N; de Winter RJ; Ormiston JA; Serruys PW; Onuma Y EuroIntervention; 2017 Apr; 12(18):e2244-e2252. PubMed ID: 27993756 [TBL] [Abstract][Full Text] [Related]
30. Early vascular responses to everolimus-eluting cobalt-chromium stent in the culprit lesions of st-elevation myocardial infarction: results from a multicenter prospective optical coherence tomography study (MECHANISM-AMI 2-week follow-up study). Morino Y; Terashita D; Otake H; Kikuchi T; Fusazaki T; Kuriyama N; Suzuki T; Ito Y; Hibi K; Tanaka H; Ishihara S; Kataoka T; Morita T; Otsuka Y; Hayashi T; Tanabe K; Shinke T Cardiovasc Interv Ther; 2019 Jan; 34(1):14-24. PubMed ID: 29318464 [TBL] [Abstract][Full Text] [Related]
31. Second generation, sirolimus-eluting, bioresorbable Tyrocore scaffold implantation in patients with ST-segment elevation myocardial infarction: Baseline OCT and 30-day clinical outcomes - A FANTOM STEMI pilot study. Koltowski L; Tomaniak M; Ochijewicz D; Maksym J; Roleder T; Zaleska M; Proniewska K; Opolski G; Kochman J Catheter Cardiovasc Interv; 2020 Jul; 96(1):E1-E7. PubMed ID: 31343827 [TBL] [Abstract][Full Text] [Related]
32. Five-Year Optical Coherence Tomography in Patients With ST-Segment-Elevation Myocardial Infarction Treated With Bare-Metal Versus Everolimus-Eluting Stents. Gomez-Lara J; Brugaletta S; Jacobi F; Ortega-Paz L; Ñato M; Roura G; Romaguera R; Ferreiro JL; Teruel L; Gracida M; Martin-Yuste V; Freixa X; Masotti M; Gomez-Hospital JA; Sabate M; Cequier A Circ Cardiovasc Interv; 2016 Oct; 9(10):. PubMed ID: 27702766 [TBL] [Abstract][Full Text] [Related]
33. Clinical Comparison With Short-Term Follow-Up of Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Stent in Primary Percutaneous Coronary Interventions. Cortese B; Ielasi A; Romagnoli E; Varricchio A; Cuculo A; Loi B; Pisano F; Corrado D; Sesana M; La Vecchia L; Summaria F; Tespili M; Silva Orrego P; Tognoni G; Steffenino G Am J Cardiol; 2015 Sep; 116(5):705-10. PubMed ID: 26100584 [TBL] [Abstract][Full Text] [Related]
34. Structural and Functional Evaluation of Coronary Arteries Treated With ABSORB Bioresorbable Vascular Scaffold at 5-Year Follow-Up. Goncalves-Ramírez LR; Amat-Santos IJ; Altisent OA; Gutiérrez H; Pérez de Prado A; Adeliño R; Gómez I; Fernández-Vázquez F; San Román A; Puri R Am J Cardiol; 2022 Nov; 182():1-7. PubMed ID: 36075756 [TBL] [Abstract][Full Text] [Related]
35. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. Onuma Y; Sotomi Y; Shiomi H; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Igarashi K; Kozuma K; Tanabe K; Kusano H; Rapoza R; Popma JJ; Stone GW; Simonton C; Serruys PW; Kimura T EuroIntervention; 2016 Oct; 12(9):1090-1101. PubMed ID: 27597270 [TBL] [Abstract][Full Text] [Related]
36. The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial. Suwannasom P; Sotomi Y; Ishibashi Y; Cavalcante R; Albuquerque FN; Macaya C; Ormiston JA; Hill J; Lang IM; Egred M; Fajadet J; Lesiak M; Tijssen JG; Wykrzykowska JJ; de Winter RJ; Chevalier B; Serruys PW; Onuma Y JACC Cardiovasc Interv; 2016 Jun; 9(12):1231-1242. PubMed ID: 27262861 [TBL] [Abstract][Full Text] [Related]
37. Bioresorbable vascular scaffolds in coronary chronic total occlusions revascularization: safety assessment related to struts coverage and apposition in 6-month OCT follow-up. Abellas-Sequeiros RA; Ocaranza-Sanchez R; Trillo-Nouche R; Gonzalez-Juanatey C; Gonzalez-Juanatey JR Heart Vessels; 2017 Sep; 32(9):1077-1084. PubMed ID: 28432385 [TBL] [Abstract][Full Text] [Related]
38. In-Scaffold Neovascularization 24 Months After Bioresorbable Vascular Scaffold Implantation in a Patient With ST-Segment Elevation Myocardial Infarction. Tomaniak M; Kochman J; Kołtowski Ł; Pietrasik A; Rdzanek A; Filipiak KJ; Opolski G; Regar E JACC Cardiovasc Interv; 2017 Jul; 10(13):e123-e125. PubMed ID: 28624381 [No Abstract] [Full Text] [Related]
39. Bioresorbable vascular scaffolds in coronary chronic total occlusions: clinical, vasomotor and optical coherence tomography findings at three-year follow-up (ABSORB-CTO study). Gheorghe L; Millán X; Jimenez-Kockar M; Gomez-Lara J; Arzamendi D; Danduch L; Agudelo V; Serra A EuroIntervention; 2019 May; 15(1):99-107. PubMed ID: 30277460 [TBL] [Abstract][Full Text] [Related]
40. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]